Cellebrite DI Ltd. (CLBT)
| Market Cap | 2.69B -16.8% |
| Revenue (ttm) | 514.29M +17.8% |
| Net Income | 58.25M |
| EPS | 0.23 |
| Shares Out | 249.44M |
| PE Ratio | 47.04 |
| Forward PE | 17.93 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 36,750,366 |
| Open | 10.32 |
| Previous Close | 15.25 |
| Day's Range | 9.58 - 10.83 |
| 52-Week Range | 9.58 - 19.98 |
| Beta | 1.18 |
| Analysts | Strong Buy |
| Price Target | 16.86 (+56.11%) |
| Earnings Date | Aug 13, 2026 |
About CLBT
Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company provides a platform of software solutions used to access, collect, review, extract, decode, decrypt, analyze, share and manage digital evidence across the investigative lifecycle for a range of investigations, such as child exploitation, homicide, anti-terror, border control, sexual crimes, organized crime, human trafficking, corporate security, and intellectual property thef... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CLBT stock is "Strong Buy." The 12-month stock price target is $16.86, which is an increase of 56.11% from the latest price.
News
Cellebrite DI Earnings Call Transcript: Q2 2026
Q2 saw 21% ARR growth to $508M and 16% revenue growth, but missed guidance due to delayed large government deals and lower-than-expected Inseyets uplift. Full-year ARR and revenue outlooks were lowered, but adjusted EBITDA guidance was raised, reflecting disciplined investment and strong new product adoption.
Cellebrite DI Earnings release: Q2 2026
Cellebrite DI released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Cellebrite DI Slides: Q2 2026
Cellebrite DI has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
Cellebrite Appoints Shiven Ramji Chief Executive Officer, Succeeding Thomas E. Hogan
Company Reports Second-Quarter 2026 Results ; Company Lowers Full-Year 2026 ARR and Revenue Outlook and Raises Adjusted EBITDA Target TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 13, 2026 /PRNewsw...
Cellebrite price target raised to $22 from $20 at DA Davidson
DA Davidson analyst Rudy Kessinger raised the firm’s price target on Cellebrite (CLBT) to $22 from $20 and keeps a Buy rating on the shares.
Cellebrite to Report Second-Quarter 2026 Financial Results on August 13, 2026
TYSONS CORNER, Va. and PETAH TIKVA, Israel, July 21, 2026 /PRNewswire/ -- Cellebrite DI Ltd.
Cellebrite expands partnership with SkySafe
Cellebrite (CLBT) DI announced an expanded partnership with SkySafe. The exclusive partnership combines advanced digital forensics with advanced drone detection, deep analysis and drone activity, equi...
Cellebrite Expands Exclusive SkySafe Partnership to Deliver Immediate Drone Detection and Airspace Intelligence for Digital Investigations at Scale
The partnership unifies what happens in the sky with what's stored on the drone in a single investigative workflow TYSONS CORNER, Va. and PETAH TIKVA, Israel, July 8, 2026 /PRNewswire/ -- Cellebrite D...
Cellebrite DI Transcript: Mizuho Technology Conference 2026
The session highlighted advanced digital evidence extraction, AI-driven analytics, and a shift to consumption-based models. New products like Genesis expand investigative capabilities, while acquisitions and R&D keep pace with evolving threats and device types. Financial strength and a vertical focus on law enforcement set high barriers to entry.
Cellebrite DI Transcript: Investor update
The platform has evolved from mobile forensics to a comprehensive, AI-powered investigation suite, broadening its user base and accelerating case resolution. New products like Genesis and Guardian Investigate deliver rapid, actionable insights, while robust compliance and technical innovation drive adoption.
Cellebrite Launches the New Age of Investigations with Genesis, Now Generally Available
Reduces investigative workloads from weeks to minutes accelerating investigations like never before TYSONS CORNER, Va. and PETAH TIKVA, Israel, June 10, 2026 /PRNewswire/ -- Cellebrite DI Ltd.
Cellebrite Announces Upcoming Investor Events on June 10, 2026
TYSONS CORNER, Va. and PETAH TIKVA, Israel, June 5, 2026 /PRNewswire/ -- Cellebrite DI Ltd.
Cellebrite DI Transcript: 46th Annual William Blair Growth Stock Conference
The session highlighted a strategic shift to a comprehensive, AI-driven investigative platform, with rapid adoption of new products like Genesis and expanded capabilities through acquisitions. FedRAMP High Authorization positions the company for significant federal opportunities, while AI integration is set to drive both operational efficiency and margin expansion.
Cellebrite DI Transcript: TD Cowen's 54th Annual Technology, Media & Telecom Conference
The company is accelerating growth through a robust, AI-driven public safety platform, expanding its product suite and customer base globally. Genesis, its new AI tool, is transforming investigations, while FedRAMP authorization opens significant U.S. federal opportunities.
Cellebrite initiated with a Buy at DA Davidson
DA Davidson initiated coverage of Cellebrite (CLBT) with a Buy rating and $20 price target The company’s total addressable market is large, growing, and likely understated, the analyst tells investors...
Cellebrite DI Transcript: J.P. Morgan 54th Annual Global Technology, Media and Communications Conference
Digital intelligence solutions provider reported 21% ARR growth and strong profitability, driven by new AI and cloud products, federal market recovery, and robust international expansion. FedRAMP Level 4 certification and legislative tailwinds position the company for further growth.
Cellebrite price target lowered to $15 from $18 at Needham
Needham lowered the firm’s price target on Cellebrite (CLBT) to $15 from $18 and keeps a Buy rating on the shares. The company’s Q1 results outperformed consensus estimates across the…
Cellebrite reports Q1 non-GAAP EPS 12c, consensus 9c
Reports Q1 revenue $128.3M, consensus $127.03M. “Cellebrite’s (CLBT) Q1 of 2026 was highlighted by the delivery of a substantial slate of innovative offerings and new capabilities to the marketplace,”...
Cellebrite DI Earnings Call Transcript: Q1 2026
Q1 2026 saw 21% ARR growth and 29% higher adjusted EBITDA, driven by strong AI product launches and robust federal and EMEA rebounds. Guidance for Q2 and the full year remains strong, with new products and FedRAMP certification fueling optimism.
Cellebrite DI Earnings release: Q1 2026
Cellebrite DI released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Cellebrite DI Slides: Q1 2026
Cellebrite DI has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 14, 2026.
Cellebrite Announces First-Quarter 2026 Results
First-Quarter ARR Growth of 21% and TTM Free Cash Flow Margin of 32% Q2 Outlook Highlights ARR Acceleration TYSONS CORNER, Va. and PETAH TIKVA, Israel, May 14, 2026 /PRNewswire/ -- Cellebrite DI Ltd.
Cellebrite Announces Participation in Upcoming Investor Conferences
TYSONS CORNER, Va. and PETAH TIKVA, Israel, May 8, 2026 /PRNewswire/ -- Cellebrite DI Ltd.
Cellebrite’s Government Cloud achieves FedRAMP High Authorization
Cellebrite’s (CLBT) Cellebrite Government Cloud, or CGC, platform has achieved FedRAMP High Authorization, the federal government’s highly stringent cloud security standard, with the U.S. Department o...
Cellebrite Government Cloud Achieves FedRAMP High Authorization
Authorization at the highest security standard in the FedRAMP framework enables federal government examiners, investigators, intelligence analysts and field agents to securely collaborate and act on d...